PUBLIKATIONEN
P U B L I K A T I O N S L I S T E von Dr. Anna Rab (geb. Sieder)
| • | Rab A, Kalipciyan M, Steger GG, Mader RM. Downregulation of base excision repair by antisense oligonucleotides in chemoresistant colorectal cancer in vitro. (submitted) |
| • | Dallinger S, Sieder A, Strametz J, Bayerle-Eder M, Wolzt M, Schmetterer L. Vasodilator effects of L-arginine are stereospecific and augmented by insulin in humans. Am J Physiol Endocrinol Metab. 2003 Jun;284(6):E1106-11. |
| • | Rab A, Dallinger S, Polak K, Pleiner J, Polska E, Wolzt M, Schmetterer L.Specific endothelin ETA receptor antagonism does not modulate insulin-induced hemodynamic effects in the human kidney, eye or forearm. J Pharmacol Exp Ther. 2004 Feb 2 |
| • | Polska E, Luksch A, Ehrlich P, Sieder A, Schmetterer L. Measurements in the peripheral retina using LDF and laser interferometry are mainly influenced by the choroidal circulation. Curr Eye Res. 2002 Apr;24(4):318-23. |
| • | Fuchsjager-Mayrl G, Pleiner J, Wiesinger GF, Sieder AE, Quittan M, Nuhr MJ, Francesconi C, Seit HP, Francesconi M, Schmetterer L, Wolzt M. Exercise training improves vascular endothelial function in patients with type 1 diabetes. Diabetes Care. 2002 Oct;25(10):1795-801. |
| • | Bayerle-Eder M, Fuchsjager-Mayrl G, Sieder A, Polska E, Roden M, Stulnig T, Bischof MG, Waldhausl W, Schmetterer L, Wolzt M.Effect of pravastatin on responsiveness to N-monomethyl-L-arginine in patients with hypercholesterolaemia. Atherosclerosis. 2002 Jan;160(1):177-84. |
| • | Pleiner J, Heere-Ress E, Langenberger H, Sieder AE, Bayerle-Eder M, Mittermayer F, Fuchsjager-Mayrl G, Bohm J, Jansen B, Wolzt M.Adrenoceptor hyporeactivity is responsible for Escherichia coli endotoxin-induced acute vascular dysfunction in humans. Arterioscler Thromb Vasc Biol. 2002 Jan;22(1):95-100. |
| • | Havel C, Sieder A, Herkner H, Domanovits H, Schmied M, Segel R, Koreny M, Laggner AN, Mullner M.Which treatment for low back pain? A factorial randomised controlled trial comparing intravenous analgesics with oral analgesics in the emergency department and a centrally acting muscle relaxant with placebo over three days. BMC Emerg Med. 2001;1(1):2. Epub 2001 Nov 09. |
| • | Hollenstein U, Homoncik M, Stohlawetz PJ, Marsik C, Sieder A, Eichler HG, Jilma B. Endotoxin down-modulates granulocyte colony-stimulating factor receptor (CD114) on human neutrophiles. J Infect. Dis. 182(1):343-346 (2000) |
| • | Locker GG, Kapiotis S, Veitl M, Mader RM, Stoiser B, Kofler J, Sieder A, Rainer H, Steger GG, Mannhalter C, Wagner OF. Activation of endothelium by immunotherapy with interleukin-2 in patient with malignant disorders. Brit J Haematology 105, 912-919 (1999) |
| • | Mader RM, Sieder A, Braun J, Rizovski B, Kalipciyan M, Mueller MW, Jakesz R, Rainer H , Steger GG: Transcription and activity of 5-fluorouracil converting enzymes regulate fluoropyrimidine resistance in colon cancer in vitro. Biochem Pharmacol 54: 1233-1242 (1997). |
| • | Locker GJ, Mader RM, Braun J, Sieder A, Marosi C, Rainer H, Gnant MFX, Jakesz R, Steger GG: New mucin-like cancer associated antigens (CA M 26, CA M 29 and CA 549) and a new proliferation marker (TPS) in patients with primary or advanced breast cancer. Oncology 52, 140-144 (1995). |
| • | Mader RM, Steger GG, Rizovski B, Sieder A, Locker G, Jakesz R, Rainer H: Pharma-cokinetics of [R,S]-leucovorin versus [S]-leucovorin in patients with advanced gastrointestinal cancer. Brit J Clin Pharmacol 37, 243-248 (1994). |
| • | Steger GG, Locker G, Rainer H, Mader RM, Sieder A, Gnant MF, Aberer W, Jakesz R: Cutaneuos reactions to GM-CSF in inflammatory breast cancer. Letter im New England Journal of Medicine 327, 286 (1992). |
| • | Mader R, Steger GG, Rizovski B, Sieder A, Schiessel R, Jakesz R, Rainer H: Pharmakokinetik und Pharmakodynamik der Modulation von 5-Fluoruracil mittels Leucovorin. Acta Chirurgica Austriaca 5/6, 211-213 (1991). |
| • | Steger GG, Sieder A, Mader RM, Marosi Ch, Locker G, Blöchl-Daum B, Rainer H: Immunosuppressive acidic protein and human placental alkaline phosphatase compared with CA 125 in ovaraian cancer: an evaluation of 247 cases. J Tumor Marker Oncology 6, 189-193 (1991). |
| • | Steger GG, Sieder A, Mader RM: Immunoacidic protein (IAP) and human placental alkaline phosphatase (hPLAP) compared with CA 125 in ovarian cancer. J Tumor Marker Oncol 5, 228 (1990). |
| • | Rab A. Das Frauenherz schlägt anders. Vortrag am 23. Kärntner Herztag, 11.11.2012 |
| • | Rab A. Effiziente Differentialdiagnostik in der Praxis und im Krankenhaus. Vortrag Collegium Publicum Wien, 20.11.2010. |
| • | Rab A. Was bedeutet Stammzellentherapie? Handelt es sich um „das Allheilmittel der Zukunft“ oder um ein Forschungsprojekt? Vortrag Bad Kissingen, 2. Kardiologisches Symposium des Rhön-Klinikum Bad Neustadt/Saale (Deutschland). |
| • | Wolf C, Rab A, Nemec M, H.Weber. Preventing Stent thrombosis by faster endothelialisation with a new biogradable polymer Stent, AHA 2009 |
| • | Sieder A. Remifentanil/Midazolam compared to Sufentanil/Midazolam for long term sedation in intensive care unit patients. Vortrag: Arterielle Spiegelbestimmungen von Remifentanil, Sufentanil und Midazolam (inklusive Metabolite). APA 2001, 27.-28. April, Hörsaalzentrum AKH |
| • | Sieder A, Steger GG, Mader RM: Modulation of 5-fluorouracil resistance by antisense oligonucleotide inhibition of the base excision DNA repair. Poster: IV Congress of the European Association for Clinical Pharmacology and Therapeutics, Florenz 15-20 Juli 2000 |
| • | Sieder A. DNA Reparaturmechanismen als Träger der Resistenz gegen 5-Fluoruracil in kolorektalen Tumoren. Wilhelm Auerswald Preis 1999, Vortrag in der Gesellschaft der Ärzte am 24.Mai 2000 |
| • | Shehata M, Schwarzmeier JD, Hilgarth M, Hubmann R, Sieder A, Schlagbauer-Wadl H, Berger R. Mechanism of bisphosphonate-induced apoptosis in neoplastic cells. XXVII European Symposium on Calcified Tissues, Tampere, Finland, 6-10 Mai 2000. |
| • | Locker GG, Mader RM, Wagner O, Sieder A, Rainer H, Höcker P, Wagner A, Steger GG: Cytokine serum levels in patients with malignant disease during therapy with interleukin-2 and autologous lymphocyte concentrates. Poster zur Hämatologisch-Onkologischen Frühjahrstagung in Wien, 26 und 27. März 1993. |
| • | Mader RM, Steger GG, Sieder A, Rizovski B, Jakesz R, Hamilton G, Roth E, Rainer H: Comparison of the 5-fluorouracil modulating agents 5-methyltetrahydrofolate and leucovorin. Vortrag auf der Hämatologisch-Onkologischen Frühjahrstagung in Wien, 26 und 27. März 1993. |
| • | Mader RM, Steger GG, Sieder A, Ovissi L, Roth E, Hamilton G, Jakesz R, Rainer H: Impact of the anabolism of 5-fluorouracil on cytotoxicity in colorectal tumor cells in vitro. Vortrag am Annual Congress of the Austrian Society of Hematology and Oncology, Graz, September 27-30, 1992. Veröffentlicht in: Ann Hematol 65 (Suppl.), 4 (1992). |
| • | Mader RM, Steger GG, Sieder A, Rizovski B, Hamilton G, Roth E, Jakesz R, Rainer H: Fluoropyrimidine resistance. Vortrag am 26th Annual Meeting of the European Society for Clinical Investigation, Vienna, April 1-4, 1992. |
| • | Mader RM, Steger GG, Rizovski B, Sieder A, Hamilton G, Roth E, Jakesz R, Rainer H: Stereospecific protein binding of [R,S]-leucovorin. 7th NCI-EORTC symposium on new drugs in cancer therapy, Amsterdam, March 17-20, 1992. |
| • | Franz M, Malec M, Sieder A, Zavinka C, Windberger U, Schmetterer L, Podesser BK. Evaluation fluoreszierender Mikrosphären an der Ratte – Messung des regionalen Blutflusses in verschiedenen Organsystemen. Acta Chir. Austriaca, Vol. 33, Suppl No 180, 2001 |
| • | Sieder A, Steger GG, Mader RM: Modulation of 5-fluorouracil resistance by antisense oligonucleotide inhibition of the base excision DNA repair. BJCP, Suppl. 1, abstract 980 (2000). |
| • | Shehata M, Schwarzmeier JD, Hilgarth M, Hubmann R, Sieder A, Schlagbauer-Wadl H, Berger R. Mechanism of bisphosphonate-induced apoptosis in neoplastic cells. Calcified Tissue International, Vol. 66, Suppl. 1 (2000). |
| • | Mader RM, Steger GG, Braun J, Sieder A, Roth E, Hamilton G, Jakesz R, Rainer H: The pyrimidine network in colorectal tumors in vitro. Proc Am Ass Cancer Res 35, 2684 (1994). |
| • | Mader RM, Steger GG, Sieder A, Rizovski B, Hamilton G, Roth E, Jakesz R, Rainer H: Circumvention of fluoropyrimidine resistance and its biochemical modulation. Proc Am Ass Cancer Res 34, 2475 (1993). |
| • | Steger GG, Mader RM, Rizovski B, Sieder A, Hamilton G, Roth E, Jakesz R, Rainer H: Stereospecific protein binding of [R,S]-leucovorin and [R,S]-5-methyltetrahydrofolate. Proc Am Ass Cancer Res 34, 2342 (1993). |
| • | Locker G, Mader RM, Braun J, Sieder A, Rainer H, Gnant M, Jakesz R, Steger GG: Mucin-like cancer associated antigens (CA 549, CA M 26, CA M 29) in sera of patients with primary or advanced breast cancer. Ann Hematol 65 (Suppl.), 57 (1992). |
| • | Steger GG, Sieder A, Mader RM, Locker G, Czernin J, Rainer H, Derfler K, Gnant M, Schiessel R, Jakesz R: Phase I and phase II studies of interferon-alpha and fluorouracil/leucovorin in colorectal cancer. Ann Hematol 65 (Suppl.), 6 (1992). |
| • | Mader RM, Steger GG, Sieder A, Ovissi L, Roth E, Hamilton G, Jakesz R, Rainer H: Impact of the anabolism of 5-fluorouracil on cytotoxicity in colorectal tumor cells in vitro. Ann Hematol 65 (Suppl.), 4 (1992). |
| • | Mader RM, Steger GG, Sieder A, Rizovski B, Hamilton G, Roth E, Jakesz R, Rainer H: Fluoropyrimidine resistance. Eur J Clin Invest 22 (4), abstract 210 (1992). |
| • | Mader RM, Steger GG, Rizovski B, Sieder A, Hamilton G, Roth E, Jakesz R, Rainer H: Stereospecific protein binding of [R,S]-leucovorin. Annals of Oncology 3 (Suppl.1), abstract 300 (1992). |
